PHARMAROTH LABS, INC. Inactive Instrument
PharmaRoth Labs, Inc. Stock Other OTC
Equities
ROTH
US71715Y1029
Pharmaceuticals
Financials (USD)
| Sales 2009 | - | Sales 2010 | - | Capitalization | 5.74M |
|---|---|---|---|---|---|
| Net income 2009 | - | Net income 2010 | - | EV / Sales 2009 | - |
| Net Debt 2009 | 12.5K | Net Debt 2010 | 286K | EV / Sales 2010 | - |
| P/E ratio 2009 |
-777
x | P/E ratio 2010 |
-7.8
x | Employees | - |
| Yield 2009 * |
-
| Yield 2010 |
-
| Free-Float | 30.93% |
More Fundamentals
* Assessed data
More news
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 10-08-30 | |
Barry W. Hall
DFI | Director of Finance/CFO | 76 | 13-01-21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 10-08-30 |
PharmaRoth Labs, Inc. is a nutraceutical company that is focused on the prevention and treatment of healthcare diabetes. The Company is engaged in the production, marketing, and distribution of Sucanon, a clinically-tested herbal-based nutraceutical treatment for type II diabetes. Sucanon is a medication that helps the body make better use of its own insulin, the hormone that controls blood sugar levels.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| +26.36% | 672B | |
| +25.87% | 570B | |
| -5.33% | 360B | |
| +16.35% | 321B | |
| +8.60% | 300B | |
| +7.09% | 217B | |
| -9.12% | 204B | |
| +5.01% | 199B | |
| -8.85% | 149B |
